1. Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors
2. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
3. a Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971
in Combination With Either Osimertinib in Participants With Unresectable,
Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With
Cetuximab in Participants With Metastatic Colorectal Cancer, NCT05954871, 2023.
4. bF. Hoffmann-La Roche Ltd A Study
to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971
in Combination With Atezolizumab in Participants With Locally Advanced
or Metastatic Solid Tumors, NCT05487235, 2022.
5. c A Phase
Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety,
Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in
Combination With Other Anti-cancer Therapies in Patients With Advanced
or Metastatic Solid Tumors With a KRAS G12C Mutation, NCT04449874, 2020.